ESC 2021 | ISAR-REACT 5: Prasugrel Superior to Ticagrelor in ACS across Kidney Function Spectrum

When we have to choose between two potent P2Y12 receptor inhibitors for a patient undergoing ACS with a planned invasive strategy, kidney function should not interfere in this decision. 

The main findings of this study were that prasugrel has lower risk of all cause death, MI or stroke, and also had a similar risk of bleeding compared against ticagrelor. These findings were consistent with those of low and intermediate risk patients or high glomerular filtration. 

These findings were presented during the ESC 2021 scientific sessions and were simultaneously published in JACC: Cardiovascular Interventions.

Patients with altered kidney function are challenging for multiple reasons: on the one hand, they present higher ischemic risk and on the one hand, a higher risk of bleeding, given drug pharmacokinetics. 

For this analysis, the authors divided 4,012 participants according to glomerular filtration into 3 groups: low (<60 mL/min/1.73; m2; 760 patients), intermediate (60 to 90 mL/min/1.73 m2; 1968 patients) and high (>90 mL/min/1.73 m2; 1284 patients).

As expected, the worse the glomerular filtration, the bigger the number of events, both ischemic and hemorrhagic.  

However, this did not affect the relative efficacy of prasugrel. Moreover, its biggest advantage was in patients with worse glomerular filtration. 


Read also: ESC 2021 | TOMAHAWK: Angiography After Resuscitated Patients from Out-Of-Hospital Cardiac Arrest with No ST Elevation.


Specifically, in this last subgroup, the rate of all cause death, MI or stroke was significantly higher in patients receiving ticagrelor vs prasugrel (20.5% vs 14.7%; HR 1.47; CI 95% 1.04 to 2.08), with no cost in bleeding BARC 3-5 (10.4% vs 8.4%; HR 1.24; CI 95% 0.73-2.09).

After a few years of absolute dominion of ticagrelor, several studies have slowly brought back prasugrel and clopidogrel to the current clinical arena.  

Original Title: Ticagrelor or prasugrel in patients with acute coronary syndrome in relation to estimated glomerular filtration rate. 

Reference: Wöhrle J. J Am Coll Cardiol Intv. 2021; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...